14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GRML vs HCTI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, GRML (GRML) captures the overall head-to-head institutional edge over Healthcare Triangle, Inc. (HCTI) on higher Unified Composite conviction (56.8/100 HOLD vs. 36.5/100 SELL) after splitting the core matrix 2–6 (led by Options & Positioning), while HCTI wins 5–1 across the 6-pillar growth and valuation breakdown. GRML trades at $3.50 (N/M Forward P/E, N/A operating margin) versus HCTI at $3.33 (N/M Forward P/E, -45.2% operating margin).
Growth vs. Quality Trade-Off: GRML earns the overall head-to-head edge with a stronger Unified Composite Score (56.8/100 HOLD vs. HCTI 36.5/100 SELL) and -5.29β · 95% Vol risk profile, whereas HCTI leads top-line expansion (+161.3% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5); meanwhile HCTI is in a Breakdown options structure phase (RSI 50.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRML vs HCTI. Trailing 12-month operating profitability (GRML N/A vs HCTI -45.2%) and valuation multiples (GRML N/M vs HCTI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Health Information Services value chain with $3.2M market capitalization and -45.2% operating margin.
OpEx & R&D Reinvestment67.5% of Rev ($21M)
90D Engineering Disclosures0 Published
Investor FAQ GRML vs HCTI Key Questions & Quantitative Answers
As of Nov 16, 2026, GRML (GRML) captures the overall head-to-head institutional edge over Healthcare Triangle, Inc. (HCTI) on higher Unified Composite conviction (56.8/100 HOLD vs. 36.5/100 SELL) after splitting the core matrix 2–6 (led by Options & Positioning), while HCTI wins 5–1 across the 6-pillar growth and valuation breakdown. GRML trades at $3.50 (N/M Forward P/E, N/A operating margin) versus HCTI at $3.33 (N/M Forward P/E, -45.2% operating margin). Growth vs. Quality Trade-Off: GRML earns the overall head-to-head edge with a stronger Unified Composite Score (56.8/100 HOLD vs. HCTI 36.5/100 SELL) and -5.29β · 95% Vol risk profile, whereas HCTI leads top-line expansion (+161.3% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5); meanwhile HCTI is in a Breakdown options structure phase (RSI 50.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
HCTI leads the Growth & Scale pillar: GRML posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with HCTI at +161.3% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (22.3% gross margin, -45.2% operating margin). On trailing 12-month operating scale, GRML generates N/A in USD-normalized revenue versus $31M for HCTI. In operating R&D and SG&A reinvestment, GRML deploys N/A (0 90-day corporate R&D disclosures) versus 67.5% of Rev ($21M) (0 disclosures) for HCTI.
HCTI screens cheaper on headline valuation multiples. GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HCTI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-38.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRML (N/A ROE) versus HCTI (-59.9% ROE) capital efficiency.
In options market volatility and institutional positioning, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.29β · 95% Vol realized risk). By comparison, HCTI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (10.88β · 6721% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.